aTyr Pharma announced that its partner Kyorin Pharmaceutical has dosed the first patient in Japan in EFZO-FIT, a global pivotal Phase 3 study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease, ILD. This achievement has triggered a $10M milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin. "We are very pleased with Kyorin’s timely start to EFZO-FIT and are happy to have centers open for enrollment in Japan, which is an important part of this large, global study," said Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. "Kyorin is responsible for the clinical development of efzofitimod for ILD in Japan and is an essential partner for aTyr as we work to bring this transformative, disease modifying therapy to sarcoidosis patients."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LIFE:
- aTyr Pharma to present new data on mechanism of action of efzofitimod
- aTyr: EPO okays use of efzofitimod with pirfenidone patent for lung inflammation
- aTyr Pharma Gains E.U. Patent Covering Use of Efzofitimod with Pirfenidone for Lung Inflammation or Fibrosis
- EC grants aTyr Pharma ODA to efzofitimod to treat sarcoidosis
- European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Sarcoidosis
